Comparative Pharmacology
Head-to-head clinical analysis: NORCEPT E 1 35 21 versus NORETHIN 1 50M 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORCEPT E 1 35 21 versus NORETHIN 1 50M 21.
NORCEPT-E 1/35 21 vs NORETHIN 1/50M-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin secretion, preventing ovulation; progestin (norethindrone) alters cervical mucus, endometrial lining, and inhibits sperm penetration.
Norethindrone is a progestin that suppresses gonadotropin release from the pituitary, inhibiting ovulation. It also induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
One tablet (norethindrone 1 mg + ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no tablets. Repeat cycle continuously.
One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Ethinyl estradiol: terminal half-life approximately 17 hours (range 13-27 hours), consistent with once-daily dosing; norethindrone: terminal half-life approximately 7.6 hours (range 5-12 hours), permitting steady-state within 5 days.
Terminal elimination half-life: 5-14 hours (mean ~8h). Clinical context: Steady-state achieved after 4-5 days; dosing interval 24 hours maintains therapeutic levels.
Renal: 50-60% as metabolites (primarily ethinyl estradiol glucuronide and norethindrone metabolites); fecal: 20-30% via biliary elimination; unchanged drug: <5%.
Renal: 50-60% as metabolites; Fecal: 30-40% (via biliary); Less than 5% unchanged in urine.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive